New insights into the secretory functions of brown adipose tissue.


Journal

The Journal of endocrinology
ISSN: 1479-6805
Titre abrégé: J Endocrinol
Pays: England
ID NLM: 0375363

Informations de publication

Date de publication:
11 2019
Historique:
received: 12 08 2019
accepted: 16 08 2019
pubmed: 17 8 2019
medline: 9 4 2020
entrez: 17 8 2019
Statut: ppublish

Résumé

In recent years, an important secretory role of brown adipose tissue (BAT) has emerged, which is consistent, to some extent, with the earlier recognition of the important secretory role of white fat. The so-called brown adipokines or 'batokines' may play an autocrine role, which may either be positive or negative, in the thermogenic function of brown adipocytes. Additionally, there is a growing recognition of the signalling molecules released by brown adipocytes that target sympathetic nerve endings (such as neuregulin-4 and S100b protein), vascular cells (e.g., bone morphogenetic protein-8b), and immune cells (e.g., C-X-C motif chemokine ligand-14) to promote the tissue remodelling associated with the adaptive BAT recruitment in response to thermogenic stimuli. Moreover, existing indications of an endocrine role of BAT are being confirmed through the release of brown adipokines acting on other distant tissues and organs; a recent example is the recognition that BAT-secreted fibroblast growth factor-21 and myostatin target the heart and skeletal muscle, respectively. The application of proteomics technologies is aiding the identification of new members of the brown adipocyte secretome, such as the extracellular matrix or complement system components. In summary, BAT can no longer be considered a mere producer of heat in response to environment or dietary challenges; it is also an active secretory tissue releasing brown adipokines with a relevant local and systemic action. The identification of the major brown adipokines and their roles is highly important for the discovery of novel candidates useful in formulating intervention strategies for metabolic diseases.

Identifiants

pubmed: 31419785
doi: 10.1530/JOE-19-0295
pii: JOE-19-0295.R1
doi:
pii:

Substances chimiques

Adipokines 0
fibroblast growth factor 21 0
Fibroblast Growth Factors 62031-54-3

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

R19-R27

Auteurs

Joan Villarroya (J)

Departament de Bioquímica i Biomedicina Molecular and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Catalonia, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Catalonia, Spain.

Rubén Cereijo (R)

Departament de Bioquímica i Biomedicina Molecular and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Catalonia, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Catalonia, Spain.

Aleix Gavaldà-Navarro (A)

Departament de Bioquímica i Biomedicina Molecular and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Catalonia, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Catalonia, Spain.

Marion Peyrou (M)

Departament de Bioquímica i Biomedicina Molecular and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Catalonia, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Catalonia, Spain.

Marta Giralt (M)

Departament de Bioquímica i Biomedicina Molecular and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Catalonia, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Catalonia, Spain.

Francesc Villarroya (F)

Departament de Bioquímica i Biomedicina Molecular and Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Catalonia, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Barcelona, Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH